On February 3, Bayer announced that the NMPA had approved a new indication for darolutamide in China, in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC). This is the third approved indication for the drug in China.
Darolutamide is an oral androgen receptor inhibitor (ARi) jointly developed by Bayer and Orion Corporation of Finland. Its unique molecular structure confers high affinity for the androgen receptor, enabling inhibition of receptor function and prostate cancer cell growth. At the same time, darolutamide shows very low blood-brain barrier penetration and has fewer adverse reactions.
This approval was based on positive results from the pivotal Phase III ARANOTE trial, a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of darolutamide plus ADT in patients with mHSPC. The primary endpoint was radiographic progression-free survival (rPFS).
Phase III ARANOTE data showed that, compared with placebo plus ADT, darolutamide plus ADT significantly reduced the risk of radiographic progression or death by 46% in mHSPC patients (HR 0.54, 95% CI 0.41–0.71; P<0.0001). Consistent rPFS benefit was observed across prespecified subgroups including both high-volume and low-volume disease.
In addition, darolutamide plus ADT showed a favorable safety profile, with a low incidence of treatment-emergent adverse events (TEAEs) comparable to placebo plus ADT, again confirming the safety and tolerability already established in multiple Phase III trials such as ARAMIS and ARASENS.
Darolutamide had already been approved in China for two prostate cancer indications. This latest approval means that darolutamide plus ADT may now be used in adult mHSPC patients regardless of whether docetaxel is also combined.
To date, darolutamide has been approved in more than 85 markets worldwide, including China, for use with ADT and docetaxel in mHSPC. It is also approved in more than 85 countries, including China, for use with ADT in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of metastasis. Global sales of darolutamide reached USD 1.641 billion in 2024, up 77% year over year.